TLRY

Tilray Brands reported a quarterly loss of $0.32 per share, significantly worse than the consensus estimate of $0.19, representing a -68.42% earnings surprise. The company also missed revenue expectations, posting $257.15 million versus the estimate of $262.35 million. With unfavorable estimate revisions, Tilray received a Zacks Rank #5 (Strong Sell) rating and has underperformed the S&P 500 by 58.9% year-to-date.

The article compares two major cannabis companies navigating industry challenges. Canopy Growth focuses on premium Canadian cannabis and European medical sales but faces internal control weaknesses and significant losses.

Tilray Brands has diversified into beverages and international markets, posting record Q1 revenue of $257M with improving margins. The author recommends Tilray as the better choice due to its larger scale, diversified revenue streams, and clearer path to profitability, though both stocks remain risky investments in a volatile industry.

SweetWater Brewing, a craft brewery brand by Tilray Brands, launched a concert sweepstakes giving fans 21+ the chance to win tickets to 2026-2027 AEG concerts at select Georgia venues including Georgia Theatre, The Eastern, Variety Playhouse, and Terminal West. Two winners will be selected with prizes valued at approximately $1,200 each, including concert tickets and travel gift cards. The sweepstakes runs through December 31, 2026.

Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.

Canopy Growth and Tilray Brands represent diverging strategies in the cannabis industry. Canopy pursues a lean, brand-focused model with emphasis on U.S. expansion, while Tilray has diversified into craft beverages and wellness products.

Both companies reported significant net losses in FY 2026 despite revenue growth, with Tilray showing better financial metrics (higher revenue, lower debt-to-equity ratio, higher gross margin) but greater business complexity. The article suggests Tilray may appeal to diversification-focused investors, while Canopy attracts those betting on pure cannabis growth, though both carry substantial risks.

Cronos Group shares rose 17% over three months following better-than-expected Q2 2026 results, with first-half revenues up 49% to $98.2 million driven by Canadian market share gains and international expansion. However, the company faces challenges including potentially unsustainable margin improvements, an Israeli anti-dumping investigation, and intensifying European competition from rivals like Village Farms and Tilray. Analysts maintain a cautious stance with unchanged earnings estimates.

Tilray Brands stock has crashed 60% this year and trades below $4, down 84% from its 52-week high. Despite record revenue of $915 million, the company posted a net loss of $105 million and burned $69 million in cash. The analyst recommends avoiding the stock due to poor growth prospects, a highly competitive Canadian market, and a questionable pivot to beverages that doesn't address fundamental business challenges.

Village Farms International (VFF) shares have surged 49% in three months, driven by 15% cannabis sales growth and expanding 51% gross margins, primarily from strong European exports led by Germany. However, the company faces increasing competition from Tilray and Canopy Growth in European markets, pricing pressure from rising industry supply, and heavy dependence on Germany for export growth. While the company holds a Zacks Rank #3 (Hold), investors should await evidence of successful market diversification before committing to longer-term positions.